Asunto(s)
Antineoplásicos/efectos adversos , Granuloma Piogénico/inducido químicamente , Enfermedades de la Uña/inducido químicamente , Taxoides/efectos adversos , Anciano , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Docetaxel , Femenino , Granuloma Piogénico/microbiología , Humanos , Infecciones por Klebsiella , Neoplasias Pulmonares/tratamiento farmacológico , Enfermedades de la Uña/microbiología , Infecciones Estafilocócicas , Resultado del TratamientoRESUMEN
BACKGROUND: Chronic urticaria is known to debilitate a person's quality of life via sleep disruption, itching lesions, fatigue, social isolation, energy loss and emotional/sexual difficulties. Once-daily desloratadine significantly improved the signs and symptoms of CIU. OBJECTIVE: Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU). Study population One-hundred twenty-one consecutive patients with CIU present for at least 6 weeks prior to inclusion and with a current flare of at least 3 weeks, were included in the study in 24 Belgian centres. RESULTS: The mean dermatology life quality index (DLQI) significantly decreased from baseline to day 7 and further to day 42. Sixty per cent and 77% of patients had a clinically significant change (i.e. a decrease of at least 2 points) at day 7 or day 42, respectively, as compared with that of day 0. Change in pruritus and size of the hives significantly correlated with the change in the score of the quality of life. One-third of patients experienced complete relief whereas in 1 of 10 patients no effect was experienced. CONCLUSIONS: Desloratadine significantly improves the quality of life of patients with chronic idiopathic urticaria as reflected by the dermatology life quality index (DLQI).
Asunto(s)
Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Loratadina/análogos & derivados , Urticaria/tratamiento farmacológico , Administración Oral , Adulto , Bélgica , Enfermedad Crónica , Esquema de Medicación , Femenino , Antagonistas de los Receptores Histamínicos H1 no Sedantes/administración & dosificación , Humanos , Loratadina/administración & dosificación , Loratadina/uso terapéutico , Masculino , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Urticaria/patología , Urticaria/psicologíaAsunto(s)
Infestaciones por Piojos/patología , Pediculus/patogenicidad , Dermatosis del Cuero Cabelludo/patología , Adulto , Animales , Niño , Humanos , Infestaciones por Piojos/complicaciones , Infestaciones por Piojos/tratamiento farmacológico , Pediculus/ultraestructura , Dermatosis del Cuero Cabelludo/tratamiento farmacológicoRESUMEN
A patient developed concomitantly chondritis of the two auricles, diffuse cutaneous vasculitis and actinic granulomas. Alterations in skin and cartilage were prominent in the elastic tissue. Anticollagen type II antibodies were absent from the serum and there was no deposit of immunoreactants in cartilages. In this form of relapsing polychondritis, the pathomechanism resembles that of diffuse actinic arteritis as proposed by O'Brien. It is concluded that relapsing polychondritis may represent a heterogeneous syndrome with regard to its pathogenesis.
